5-methoxyresorcinol mitigates postmenopausal osteoporosis through regulation of the PI3K–AKT–GSK3β signaling pathway and ROS homeostasis
Yi Li
ObjectivesOsteoporosis is a systemic skeletal disease characterized by excessive osteoclast-mediated bone resorption. This study aimed to evaluate the therapeutic potential of 5-methoxyresorcinol (MR) in osteoporosis and to clarify its underlying mechanisms.MethodsNetwork pharmacology analysis was performed to identify shared targets between MR and osteoporosis. In vitro experiments using bone marrow-derived macrophages were performed to assess the effects of MR on osteoclast differentiation and